{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:10:51Z","timestamp":1788523851529,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T00:00:00Z","timestamp":1441670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s13679-015-0177-4","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T21:51:39Z","timestamp":1441662699000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Horizons in the Pharmacotherapy of Obesity"],"prefix":"10.1007","volume":"4","author":[{"given":"Jonathan R. S.","family":"Arch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,8]]},"reference":[{"key":"177_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pharmthera.2011.04.004","volume":"131","author":"JC Clapham","year":"2011","unstructured":"Clapham JC, Arch JR. Targeting thermogenesis and related pathways in anti-obesity drug discovery. Pharmacol Ther. 2011;131:295\u2013308.","journal-title":"Pharmacol Ther"},{"key":"177_CR2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","volume":"5","author":"RJ Rodgers","year":"2012","unstructured":"Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5:621\u20136.","journal-title":"Dis Model Mech"},{"key":"177_CR3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2042098613489721","volume":"4","author":"BM Cheung","year":"2013","unstructured":"Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4:171\u201381.","journal-title":"Ther Adv Drug Saf"},{"key":"177_CR4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/phar.1342","volume":"33","author":"C Hampp","year":"2013","unstructured":"Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299\u2013307. Shows the dominance of phentermine and the limited use of orlistat in the US between 2002 and 2011.","journal-title":"Pharmacotherapy"},{"key":"177_CR5","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194\u20139.","journal-title":"BMJ"},{"key":"177_CR6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","volume":"311","author":"SZ Yanovski","year":"2014","unstructured":"Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74\u201386. Overview of drug efficacy.","journal-title":"JAMA"},{"key":"177_CR7","doi-asserted-by":"crossref","first-page":"g2646","DOI":"10.1136\/bmj.g2646","volume":"348","author":"SU Dombrowski","year":"2014","unstructured":"Dombrowski SU, Knittle K, Avenell A, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ. 2014;348:g2646.","journal-title":"BMJ"},{"key":"177_CR8","doi-asserted-by":"crossref","unstructured":"Douglas IJ, Bhaskaran K, Batterham RL, et al. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United kingdom population-based cohort. Br J Clin Pharmacol. 2014;79:1020\u20137. Efficacy may be lower in clinical practice than in clinical trials.","DOI":"10.1111\/bcp.12578"},{"key":"177_CR9","unstructured":"Top 100 diet pills Cametor review. Available at http:\/\/top100dietpills.com\/cametor-review\/ . Accessed 14 Apr 2015."},{"key":"177_CR10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijo.0803446","volume":"31","author":"P Kopelman","year":"2007","unstructured":"Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes. 2007;31:494\u20139.","journal-title":"Int J Obes"},{"key":"177_CR11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/oby.2009.155","volume":"18","author":"P Kopelman","year":"2010","unstructured":"Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18:108\u201315.","journal-title":"Obesity (Silver Spring)"},{"key":"177_CR12","doi-asserted-by":"crossref","first-page":"f5140","DOI":"10.1136\/bmj.f5140","volume":"347","author":"SM Wolfe","year":"2013","unstructured":"Wolfe SM. When EMA and FDA decisions conflict: differences in patients or in regulation? BMJ. 2013;347:f5140.","journal-title":"BMJ"},{"key":"177_CR13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jamainternmed.2013.14629","volume":"174","author":"S Woloshin","year":"2014","unstructured":"Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med. 2014;174:615\u20139.","journal-title":"JAMA Intern Med"},{"key":"177_CR14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cjca.2014.11.010","volume":"31","author":"A Pucci","year":"2015","unstructured":"Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31:142\u201352. Authoritative. Includes analysis of the differing stances of the FDA and EMA.","journal-title":"Can J Cardiol"},{"key":"177_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.10.2817","volume":"126","author":"L Aronne","year":"2014","unstructured":"Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med. 2014;126:7\u201318.","journal-title":"Postgrad Med"},{"key":"177_CR16","unstructured":"Vivus Investor relations. Financial information. Available at http:\/\/ir.vivus.com\/financials.cfm . Accessed 14 Apr 2015."},{"key":"177_CR17","unstructured":"Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity among adults: United States, 2011\u20132012. NCHS Data Brief: 2013; 1\u20138."},{"key":"177_CR18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5694\/mja13.00193","volume":"201","author":"SL Neoh","year":"2014","unstructured":"Neoh SL, Sumithran P, Haywood CJ, et al. Combination phentermine and topiramate for weight maintenance: the first Australian experience. Med J Aust. 2014;201:224\u20136.","journal-title":"Med J Aust"},{"key":"177_CR19","unstructured":"FiercePharma: arena narrows loss as Belviq sales pick up. Available at http:\/\/www.fiercepharma.com\/story\/arena-narrows-loss-belviq-sales-pick\/2014-11-03 . Accessed 14 Apr 2015."},{"key":"177_CR20","unstructured":"The Wall Street Journal: consumer groups urge Europe not to approve the orexigen diet pill. Available at http:\/\/blogs.wsj.com\/pharmalot\/2015\/01\/28\/consumer-groups-urge-europe-not-to-approve-the-orexigen-diet-pill\/ . Accessed 14 Apr 2015."},{"key":"177_CR21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2147\/DDDT.S55587","volume":"8","author":"A Caixas","year":"2014","unstructured":"Caixas A, Albert L, Capel I, et al. Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419\u201327.","journal-title":"Drug Des Devel Ther"},{"key":"177_CR22","unstructured":"Forbes: top FDA official says Orexigen study result \u201cunreliable,\u201d \u201cmisleading\u201d. Available at http:\/\/www.forbes.com\/sites\/matthewherper\/2015\/03\/05\/top-fda-official-says-orexigen-data-unreliable-likely-false\/?utm_campaign=yahootix&partner=yahootix . Accessed 14 Apr 2015."},{"key":"177_CR23","unstructured":"FiercePharma: surprise: obesity med contrave might help CV outcomes. Too bad Orexigen blabbed it. Available at http:\/\/www.fiercepharmamarketing.com\/story\/surprise-obesity-med-contrave-might-help-cv-outcomes-too-bad-orexigen-blabb\/2015-03-04 . Accessed 14 Apr 2015."},{"key":"177_CR24","first-page":"831","volume":"13","author":"JL Verpeut","year":"2014","unstructured":"Verpeut JL, Bello NT. Drug safety evaluation of naltrexone\/bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014;13:831\u201341.","journal-title":"Expert Opin Drug Saf"},{"key":"177_CR25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1517\/14712598.2014.925870","volume":"14","author":"SY Ng","year":"2014","unstructured":"Ng SY, Wilding JP. Liraglutide in the treatment of obesity. Expert Opin Biol Ther. 2014;14:1215\u201324.","journal-title":"Expert Opin Biol Ther"},{"key":"177_CR26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606\u201316.","journal-title":"Lancet"},{"key":"177_CR27","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443\u201351.","journal-title":"Int J Obes"},{"key":"177_CR28","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","volume":"63","author":"D Beiroa","year":"2014","unstructured":"Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63:3346\u201358.","journal-title":"Diabetes"},{"key":"177_CR29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2042018814559725","volume":"6","author":"JM Trujillo","year":"2015","unstructured":"Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19\u201328.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"177_CR30","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","volume":"96","author":"T Blevins","year":"2011","unstructured":"Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"177_CR31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","volume":"13","author":"A Garber","year":"2011","unstructured":"Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348\u201356.","journal-title":"Diabetes Obes Metab"},{"key":"177_CR32","unstructured":"European Medicines Agency: European Medicines Agency launches adaptive licensing pilot project. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2014\/03\/WC500163410.pdf . Accessed 14 Apr 2015."},{"key":"177_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/DMSO.S56924","volume":"7","author":"AA Joharapurkar","year":"2014","unstructured":"Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes. 2014;7:73\u201384.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"177_CR34","unstructured":"Zafgen: Beloranib. Available at http:\/\/www.zafgen.com\/zafgen\/our-approach\/beloranib Accessed 15 Apr 2015."},{"key":"177_CR35","doi-asserted-by":"crossref","unstructured":"Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab. 2015.","DOI":"10.1111\/dom.12457"},{"key":"177_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.ijo.0803695","volume":"32","author":"A Golay","year":"2008","unstructured":"Golay A. Metformin and body weight. Int J Obes. 2008;32:61\u201372.","journal-title":"Int J Obes"},{"key":"177_CR37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/dom.12198","volume":"16","author":"M Chilton","year":"2014","unstructured":"Chilton M, Dunkley A, Carter P, et al. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes Obes Metab. 2014;16:237\u201347.","journal-title":"Diabetes Obes Metab"},{"key":"177_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamapediatrics.2013.4200","volume":"168","author":"MS McDonagh","year":"2014","unstructured":"McDonagh MS, Selph S, Ozpinar A, et al. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168:178\u201384. Use of an old and relatively safe drug in children.","journal-title":"JAMA Pediatr"},{"key":"177_CR39","doi-asserted-by":"crossref","first-page":"e1140","DOI":"10.4088\/JCP.14cr09133","volume":"75","author":"JL Linneke","year":"2014","unstructured":"Linneke JL, Jorgensen GK, Csillag C. Metformin for weight loss and control in patients with mood disorder. J Clin Psychiatry. 2014;75:e1140\u20131. Metformin is surprisingly effective in controlling body weight in some patients.","journal-title":"J Clin Psychiatry"},{"key":"177_CR40","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","volume":"170","author":"LF Jarskog","year":"2013","unstructured":"Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatr. 2013;170:1032\u201340.","journal-title":"Am J Psychiatr"},{"key":"177_CR41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2125.2010.03783.x","volume":"71","author":"SK Praharaj","year":"2011","unstructured":"Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377\u201382.","journal-title":"Br J Clin Pharmacol"},{"key":"177_CR42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","volume":"138","author":"M Wang","year":"2012","unstructured":"Wang M, Tong JH, Zhu G, et al. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012;138:54\u20137.","journal-title":"Schizophr Res"},{"key":"177_CR43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4088\/JCP.09m05580","volume":"73","author":"VP Hoffmann","year":"2012","unstructured":"Hoffmann VP, Case M, Jacobson JG. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry. 2012;73:216\u201323.","journal-title":"J Clin Psychiatry"},{"key":"177_CR44","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12325-009-0070-1","volume":"26","author":"C Gross","year":"2009","unstructured":"Gross C, Blasey CM, Roe RL, et al. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959\u201369.","journal-title":"Adv Ther"},{"key":"177_CR45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","volume":"226","author":"M Poyurovsky","year":"2013","unstructured":"Poyurovsky M, Fuchs C, Pashinian A, et al. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berlin). 2013;226:615\u201322.","journal-title":"Psychopharmacology (Berlin)"},{"key":"177_CR46","doi-asserted-by":"crossref","first-page":"320803","DOI":"10.1155\/2014\/320803","volume":"2014","author":"JJ Thomas","year":"2014","unstructured":"Thomas JJ, Koh KA, Eddy KT, et al. Do DSM-5 eating disorder criteria overpathologize normative eating patterns among individuals with obesity? J Obes. 2014;2014:320803.","journal-title":"J Obes"},{"key":"177_CR47","unstructured":"FDA News Release: FDA expands uses of Vyvanse to treat binge-eating disorder. Available at http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm432543.htm . Accessed 15 Apr 2015."},{"key":"177_CR48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","volume":"72","author":"SL McElroy","year":"2015","unstructured":"McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:235\u201346.","journal-title":"JAMA Psychiatry"},{"key":"177_CR49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ijcp.12639","volume":"69","author":"L Citrome","year":"2015","unstructured":"Citrome L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69:410\u201321. Lisdexamfetamine has been approved for the treatment of binge eating disorder in the US.","journal-title":"Int J Clin Pract"},{"key":"177_CR50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/14728214.2014.879291","volume":"19","author":"DL Reas","year":"2014","unstructured":"Reas DL, Grilo CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014;19:99\u2013142.","journal-title":"Expert Opin Emerg Drugs"},{"key":"177_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brat.2014.04.002","volume":"58","author":"CM Grilo","year":"2014","unstructured":"Grilo CM, Masheb RM, White MA, et al. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. Behav Res Ther. 2014;58:1\u20139.","journal-title":"Behav Res Ther"},{"key":"177_CR52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/FBP.0000000000000029","volume":"25","author":"ME Bocarsly","year":"2014","unstructured":"Bocarsly ME, Hoebel BG, Paredes D, et al. GS 455534 selectively suppresses binge eating of palatable food and attenuates dopamine release in the accumbens of sugar-bingeing rats. Behav Pharmacol. 2014;25:147\u201357.","journal-title":"Behav Pharmacol"},{"key":"177_CR53","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/npp.2012.48","volume":"37","author":"L Piccoli","year":"2012","unstructured":"Piccoli L, Micioni Di Bonaventura MV, Cifani C, et al. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology. 2012;37:1999\u20132011.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/0884533610362239","volume":"25","author":"CW Jackson","year":"2010","unstructured":"Jackson CW, Cates M, Lorenz R. Pharmacotherapy of eating disorders. Nutr Clin Pract. 2010;25:143\u201359.","journal-title":"Nutr Clin Pract"},{"key":"177_CR55","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","volume":"71","author":"A Serretti","year":"2010","unstructured":"Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71:1259\u201372.","journal-title":"J Clin Psychiatry"},{"key":"177_CR56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamasurg.2013.3654","volume":"149","author":"SH Chang","year":"2014","unstructured":"Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275\u201387.","journal-title":"JAMA Surg"},{"key":"177_CR57","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s11695-014-1560-z","volume":"25","author":"TC Cooper","year":"2015","unstructured":"Cooper TC, Simmons EB, Webb K, et al. Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery. Obes Surg. 2015;25:1474\u201381.","journal-title":"Obes Surg."},{"key":"177_CR58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1381\/0960892053268354","volume":"15","author":"AI Guerdjikova","year":"2005","unstructured":"Guerdjikova AI, Kotwal R, McElroy SL. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg. 2005;15:273\u20137.","journal-title":"Obes Surg"},{"key":"177_CR59","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/13543784.2014.918952","volume":"23","author":"VM Jackson","year":"2014","unstructured":"Jackson VM, Price DA, Carpino PA. Investigational drugs in phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014;23:1055\u201366.","journal-title":"Expert Opin Investig Drugs"},{"key":"177_CR60","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","volume":"22","author":"HE Bays","year":"2014","unstructured":"Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014;22:1042\u20139.","journal-title":"Obesity (Silver Spring)"},{"key":"177_CR61","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1056\/NEJMoa0808949","volume":"360","author":"KA Virtanen","year":"2009","unstructured":"Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518\u201325.","journal-title":"N Engl J Med"},{"key":"177_CR62","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s13679-014-0125-8","volume":"3","author":"P Trayhurn","year":"2014","unstructured":"Trayhurn P, Arch JRS. New physiological aspects of brown adipose tissue. Curr Obes Rep. 2014;3:414\u201321.","journal-title":"Curr Obes Rep"},{"key":"177_CR63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/adip.26232","volume":"3","author":"M Rosenwald","year":"2014","unstructured":"Rosenwald M, Wolfrum C. The origin and definition of brite versus white and classical brown adipocytes. Adipocytes. 2014;3:4\u20139.","journal-title":"Adipocytes"},{"key":"177_CR64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphys.2015.00004","volume":"6","author":"AL Poher","year":"2015","unstructured":"Poher AL, Altirriba J, Veyrat-Durebex C, et al. Brown adipose tissue activity as a target for the treatment of obesity\/insulin resistance. Front Physiol. 2015;6:4.","journal-title":"Front Physiol"},{"key":"177_CR65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18:333\u201340.","journal-title":"Cell Metab"},{"key":"177_CR66","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2013.12.017","volume":"19","author":"P Lee","year":"2014","unstructured":"Lee P, Linderman JD, Smith S, et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014;19:302\u20139.","journal-title":"Cell Metab"},{"key":"177_CR67","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1038\/srep08889","volume":"5","author":"E Albrecht","year":"2015","unstructured":"Albrecht E, Norheim F, Thiede B, et al. Irisin\u2014a myth rather than an exercise-inducible myokine. Sci Rep. 2015;5:8889. An important warning about studies on irisin.","journal-title":"Sci Rep"},{"key":"177_CR68","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1006\/bbrc.1998.9667","volume":"252","author":"V Emilsson","year":"1998","unstructured":"Emilsson V, Summers RJ, Hamilton S, et al. The effects of the beta3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochem Biophys Res Commun. 1998;252:450\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"177_CR69","first-page":"137","volume":"42","author":"I Nagase","year":"1994","unstructured":"Nagase I, Sasaki N, Tsukazaki K, et al. Hyperplasia of brown adipose tissue after chronic stimulation of beta 3-adrenergic receptor in rats. Jpn J Vet Res. 1994;42:137\u201345.","journal-title":"Jpn J Vet Res"},{"key":"177_CR70","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1073\/pnas.88.23.10774","volume":"88","author":"O Champigny","year":"1991","unstructured":"Champigny O, Ricquier D, Blondel O, et al. Beta 3-adrenergic receptor stimulation restores message and expression of brown-fat mitochondrial uncoupling protein in adult dogs. Proc Natl Acad Sci U S A. 1991;88:10774\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"177_CR71","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1172\/JCI2496","volume":"101","author":"MH Fisher","year":"1998","unstructured":"Fisher MH, Amend AM, Bach TJ, et al. A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J Clin Invest. 1998;101:2387\u201393.","journal-title":"J Clin Invest"},{"key":"177_CR72","doi-asserted-by":"crossref","first-page":"e21006","DOI":"10.1371\/journal.pone.0021006","volume":"6","author":"Q Wang","year":"2011","unstructured":"Wang Q, Zhang M, Ning G, et al. Brown adipose tissue in humans is activated by elevated plasma catecholamines levels and is inversely related to central obesity. PLoS One. 2011;6:e21006.","journal-title":"PLoS One"},{"key":"177_CR73","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2967\/jnumed.106.035915","volume":"48","author":"M Hadi","year":"2007","unstructured":"Hadi M, Chen CC, Whatley M, et al. Brown fat imaging with (18)F-6-fluorodopamine PET\/CT, (18)F-FDG PET\/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. J Nucl Med. 2007;48:1077\u201383.","journal-title":"J Nucl Med"},{"key":"177_CR74","doi-asserted-by":"crossref","unstructured":"Cypess AM, Weiner LS, Roberts-Toler C, et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015;21:33\u20138. Suggests that \u03b2 3 -adrenoceptor agonists might yet have potential in the treatment of obesity.","DOI":"10.1016\/j.cmet.2014.12.009"},{"key":"177_CR75","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0140-6736(11)60812-X","volume":"378","author":"KD Hall","year":"2011","unstructured":"Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378:826\u201337.","journal-title":"Lancet"},{"key":"177_CR76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2174\/1573399810666140616144141","volume":"10","author":"MS Svane","year":"2014","unstructured":"Svane MS, Madsbad S. Bariatric surgery\u2014effects on obesity and related co-morbidities. Curr Diabetes Rev. 2014;10:208\u201314.","journal-title":"Curr Diabetes Rev"},{"key":"177_CR77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ijo.2013.205","volume":"38","author":"AD Miras","year":"2014","unstructured":"Miras AD, le Roux CW. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes. 2014;38:325\u201333.","journal-title":"Int J Obes"},{"key":"177_CR78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622313506730","volume":"5","author":"RC Troke","year":"2014","unstructured":"Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis. 2014;5:4\u201314. Authoritative overview of opportunities.","journal-title":"Ther Adv Chronic Dis"},{"key":"177_CR79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2015","unstructured":"Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21:27\u201336.","journal-title":"Nat Med"},{"key":"177_CR80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","volume":"509","author":"KK Ryan","year":"2014","unstructured":"Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509:183\u20138. Evidence from an animal model that the effect of sleeve gastrectomy on body weight is due to stimulation of the bile acid receptor FXR.","journal-title":"Nature"},{"key":"177_CR81","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","volume":"30","author":"Y Ma","year":"2013","unstructured":"Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res. 2013;30:1447\u201357.","journal-title":"Pharm Res"},{"key":"177_CR82","doi-asserted-by":"crossref","first-page":"26913","DOI":"10.1074\/jbc.M111.248203","volume":"286","author":"M Watanabe","year":"2011","unstructured":"Watanabe M, Horai Y, Houten SM, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem. 2011;286:26913\u201320.","journal-title":"J Biol Chem"},{"key":"177_CR83","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","volume":"103","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"177_CR84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","volume":"21","author":"S Fang","year":"2015","unstructured":"Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21:159\u201365. Anti-obesity effect in mice of a gut-restricted FXR agonist.","journal-title":"Nat Med"},{"key":"177_CR85","first-page":"872","volume":"46","author":"WJ O'Hara","year":"1979","unstructured":"O'Hara WJ, Allen C, Shephard RJ, et al. Fat loss in the cold\u2014a controlled study. J Appl Physiol Respir Environ Exerc Physiol. 1979;46:872\u20137.","journal-title":"J Appl Physiol Respir Environ Exerc Physiol"},{"key":"177_CR86","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tem.2014.01.001","volume":"25","author":"W Lichtenbelt","year":"2014","unstructured":"Lichtenbelt W, Kingma B, van der Lans A, et al. Cold exposure\u2014an approach to increasing energy expenditure in humans. Trends Endocrinol Metab. 2014;25:165\u20137.","journal-title":"Trends Endocrinol Metab"},{"key":"177_CR87","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1172\/JCI67803","volume":"123","author":"T Yoneshiro","year":"2013","unstructured":"Yoneshiro T, Aita S, Matsushita M, et al. Recruited brown adipose tissue as an antiobesity agent in humans. J Clin Invest. 2013;123:3404\u20138.","journal-title":"J Clin Invest"},{"key":"177_CR88","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/jphysiol.2014.283598","volume":"593","author":"DP Blondin","year":"2015","unstructured":"Blondin DP, Labbe SM, Phoenix S, et al. Contributions of white and brown adipose tissues and skeletal muscles to acute cold-induced metabolic responses in healthy men. J Physiol. 2015;593:701\u201314.","journal-title":"J Physiol"},{"key":"177_CR89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3945\/ajcn.2008.26561","volume":"89","author":"S Snitker","year":"2009","unstructured":"Snitker S, Fujishima Y, Shen H, et al. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. Am J Clin Nutr. 2009;89:45\u201350.","journal-title":"Am J Clin Nutr"},{"key":"177_CR90","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2337\/db11-1079","volume":"61","author":"PB Martinez de Morentin","year":"2012","unstructured":"Martinez de Morentin PB, Whittle AJ, Ferno J, et al. Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes. 2012;61:807\u201317.","journal-title":"Diabetes"},{"key":"177_CR91","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajcn\/87.4.801","volume":"87","author":"A Chiolero","year":"2008","unstructured":"Chiolero A, Faeh D, Paccaud F, et al. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87:801\u20139.","journal-title":"Am J Clin Nutr"},{"key":"177_CR92","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eatbeh.2013.07.007","volume":"14","author":"AM Allen","year":"2013","unstructured":"Allen AM, Kleppinger A, Lando H, et al. Effect of nicotine patch on energy intake and weight gain in postmenopausal women during smoking cessation. Eat Behav. 2013;14:420\u20133.","journal-title":"Eat Behav"},{"key":"177_CR93","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jacc.2014.06.1201","volume":"64","author":"HR Middlekauff","year":"2014","unstructured":"Middlekauff HR, Park J, Moheimani RS. Adverse effects of cigarette and noncigarette smoke exposure on the autonomic nervous system: mechanisms and implications for cardiovascular risk. J Am Coll Cardiol. 2014;64:1740\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"177_CR94","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1136\/hrt.2009.175000","volume":"95","author":"K Bhaskaran","year":"2009","unstructured":"Bhaskaran K, Hajat S, Haines A, et al. Effects of ambient temperature on the incidence of myocardial infarction. Heart. 2009;95:1760\u20139.","journal-title":"Heart"},{"key":"177_CR95","first-page":"683515","volume":"2014","author":"A Haider","year":"2014","unstructured":"Haider A, Yassin A, Doros G, et al. Effects of long-term testosterone therapy on patients with \u201cdiabesity\u201d: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515.","journal-title":"Int J Endocrinol"},{"key":"177_CR96","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.orcp.2013.10.005","volume":"8","author":"A Haider","year":"2014","unstructured":"Haider A, Saad F, Doros G, et al. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract. 2014;8:e339\u201349. Prolonged effect of testosterone on body weight.","journal-title":"Obes Res Clin Pract"},{"key":"177_CR97","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MED.0000000000000086","volume":"21","author":"AM Traish","year":"2014","unstructured":"Traish AM. Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes. 2014;21:313\u201322.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"177_CR98","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cen.12664","volume":"83","author":"M Grossmann","year":"2014","unstructured":"Grossmann M, Hoermann R, Wittert G, et al. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clin Endocrinol. 2014;83:344\u201351.","journal-title":"Clin Endocrinol."},{"issue":"Suppl 2","key":"177_CR99","first-page":"39","volume":"21","author":"M Miner","year":"2014","unstructured":"Miner M, Barkin J, Rosenberg MT. Testosterone deficiency: myth, facts, and controversy. Can J Urol. 2014;21 Suppl 2:39\u201354.","journal-title":"Can J Urol"},{"key":"177_CR100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdi.12288","volume":"6","author":"KK Cheung","year":"2015","unstructured":"Cheung KK, Luk AO, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: a review of current evidence. J Diabetes Investig. 2015;6:112\u201323. The testosterone debate.","journal-title":"J Diabetes Investig"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-015-0177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13679-015-0177-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-015-0177-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T03:39:34Z","timestamp":1567136374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13679-015-0177-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1007\/s13679-015-0177-4","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,8]]}}}